title: Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
abstract: OBJECTIVE
  To evaluate whether pre-operative chemo-radiotherapy (CRT) improves the sphincter preservation rate for distal rectal cancers within 3 cm of the anal verge.
  
  
  METHODS
  Between January 2001 and December 2004, 49 patients underwent surgery with or without pre-operative CRT for primary rectal adenocarcinoma within 3 cm of the anal verge. Clinical data were retrospectively reviewed, including stage workups, surgical records and pathology records to determine sphincter preservation rate and the factors influencing sphincter preservation.
  
  
  RESULTS
  Of 49 patients with rectal tumours within 3 cm of the anal verge, 31 underwent pre-operative CRT followed by surgery (CRT group), and 18 underwent surgery alone (non-CRT group). Sphincter preservation was possible in 11 of 31 CRT patients, and only one of 18 non-CRT patients (p=0.036). The factors most influencing sphincter preservation were reduction in tumour size (p=0.005) and downstaging (p=0.001) following pre-operative CRT.
  
  
  CONCLUSIONS
  We could observe that sphincter preservation was improved in CRT group with statistical significance when compared to non-CRT group in our study patients with rectal cancer within 3 cm of the anal verge.
authors.affiliation: Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, 809 Madu-1-dong, Ilsan-gu, Goyang, Gyeonggi 411-769, South Korea.
authors.forename: D-W
authors.initials: DW
authors.lastname: Kim
authors.forename: S-B
authors.initials: SB
authors.lastname: Lim
authors.forename: D Y
authors.initials: DY
authors.lastname: Kim
authors.forename: T H
authors.initials: TH
authors.lastname: Kim
authors.forename: K H
authors.initials: KH
authors.lastname: Jung
authors.forename: D H
authors.initials: DH
authors.lastname: Kim
authors.forename: H J
authors.initials: HJ
authors.lastname: Chang
authors.forename: D K
authors.initials: DK
authors.lastname: Sohn
authors.forename: C W
authors.initials: CW
authors.lastname: Hong
authors.forename: H S
authors.initials: HS
authors.lastname: Choi
authors.forename: S-Y
authors.initials: SY
authors.lastname: Jeong
authors.forename: J-G
authors.initials: JG
authors.lastname: Park
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001003:Anal Canal / Q000187:drug effects* / Q000528:radiation effects* / Q000601:surgery; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015986:Confounding Factors, Epidemiologic; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013505:Digestive System Surgical Procedures; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil